search
Back to results

Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris

Primary Purpose

Acne Vulgaris

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Topical Metformin Emulgel and salicylic acid
Insulin- Like growth factor (ILGF-1)
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Both males and females will be included.
  • Patients older than 18 years of age.
  • Patients with mild and moderate AV.
  • Patients with Fitzpatrick skin type III, IV and V.

Exclusion Criteria:

  • Severe acne.

    • Patients under treatment with contraceptive pills or received any kinds of systemic or topical acne medication in the last 2 months (isotretinoin, antibiotics, topical products) or corticosteroid, lithium, growth hormone, systemic metformin, vitamin B12, whey proteins, and estrogenic-progestogens.
    • History of hypertrophic/keloid scar formation.
    • Pregnancy and lactation.
    • Recurrent herpes infection.
    • Subjects with diseases that affect IGF-1 levels such as diabetes, metabolic syndrome, and acromegaly.
    • Conditions that affect liver or thyroid function, celiac disease and inflammatory bowel diseases.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Topical Metformin Emulgel and salicylic acid

    Arm Description

    Outcomes

    Primary Outcome Measures

    Efficacy of the medications
    by counting the number of inflammatory, non-inflammatory and total lesions at baseline and every 4 weeks during the treatment.
    Evaluate effect of topical metformin on decreasing serum concentration of insulin-like growth factor 1 (IGF-1)
    Evaluate effect of topical metformin on decreasing serum concentration of insulin-like growth factor 1 (IGF-1) by serum sample that will be taken from every patient before and after use of topical metformin.

    Secondary Outcome Measures

    Assessment of tolerability
    by interviewing the patients about any sign/symptom of adverse reactions (erythema, peeling, burning sensation, dryness and pruritus).
    Assessment of patient satisfaction
    by quartile grading system

    Full Information

    First Posted
    September 7, 2022
    Last Updated
    September 7, 2022
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05536193
    Brief Title
    Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris
    Official Title
    Efficacy and Safety of Topical Metformin Emulgel Versus Salicylic Acid Peeling in Treatment of Acne Vulgaris: A Split Face Study
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 10, 2022 (Anticipated)
    Primary Completion Date
    September 10, 2023 (Anticipated)
    Study Completion Date
    September 10, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Acne Vulgaris (AV ) is a common skin disorder worldwide, affecting all ages and races, considered as a long term chronic inflammatory disease of the skin.It affects nearly 85% of adolescents and about 30% of adults which is known as post- adolescent acne that often occurs in individuals aged 25 years or older particularly women. Acne lesions, which may be papules, pustules, or nodules commonly affecting face, chest and back therefore acne patients may suffer from emotional distress due to its chronicity and potential outcomes which include physical scars and persistent hyperpigmentation. The pathophysiology of AV involves four factors: abnormal follicular keratinization, hyperseborrhea, Cutibacterium acnes proliferation in the pilosebaceous unit and inflammatory mediators released into the skin. Diet is considered to be one of the main factors influencing the induction and aggravation of acne, though this is still debatable. Previous researches have focused on glycemic load, and hyperinsulinemia which lead to an increase in the concentration of insulin-like growth factor (IGF-1), which has been reported to affect androgen metabolism and lipogenesis Additionally, IGF-1 has been shown to upregulate inflammatory cytokines. A correlation between the severity of acne and the level of serum IGF-1 has also been reported. Previous clinical studies showed that a low glycemic diet can decrease both the size of the sebaceous gland and the number of inflammatory lesions
    Detailed Description
    Several treatment modalities have been used to treat AV. Topical therapies include antibiotics, azelaic acid, benzoyl peroxide, and retinoids. Systemic treatments include antibiotics, hormonal therapy, and isotretinoin in addition to physical modalities as chemical peeling . Chemical peeling is a safe, efficacious, and cost-effective procedure for treating various skin disorders and for enhancing cosmetic appearance. The principle of peeling involves controlled chemical injury to the skin in order to promote it to rejuvenate, leading to smoothening of the skin and improvement of its surface texture . As patients become more concerned about the risks and side-effects of acne medications such as antibiotics and isotretinoin, other options are needed . Metformin is an oral antihyperglycemic agent often used to treat overweight type 2 diabetic patients. It decreases hepatic glucose output and increases glucose utilization by muscles and adipocytes by increasing insulin sensitivity . Notably, metformin has been shown to suppress the mammalian target of rapamycin complex (mTORC1) activity . mTORC, also known as the mechanistic target of rapamycin, is a central cell growth regulating kinase that forms large molecular complexes in all eukaryotic cells. Rapamycin is an mTORC1-specific inhibitor, which complexes with the FK506-binding 12 kDa protein (FKBP12). Rapamycin analogs have been used clinically to treat a number of human diseases, including cancer. A wide range of both extra- and intracellular signals, including growth factors, nutrient status and stress conditions, have been shown to regulate mTORC1 to control cell growth . Hence, it is plausible that metformin through inhibition of mTORC1 improves acne as AV is one of the mechanistic target of rapamycin complex 1 (mTORC1)-driven diseases. Moreover, metformin has been suggested for the treatment of other insulin resistant-related skin disorders such as hirsutism, hidradenitis suppurativa, and acanthosis nigricans . In order to get a benefit from the anti-inflammatory effect of metformin on the skin, the best option is to enhance its dermal effects, therefore, its side effects will be less through the topical administration route . Actually, by applying a topical form of this drug on acne spots, mTORC1 over activation in skin cells can be inhibited which leads to disappearance of acne spots . Salicylic acid (SA) is a safe and efficacious peeling agent for a number of dermatological and cosmetic problems, including acne vulgaris . SA peels soften the stratum corneum and cause skin shedding by loosening the intracellular matrix and corneocyte connections which can lead to an improvement in non-inflammatory comedones . Also, SA inhibits the arachidonic acid cascade leading to a decrease in inflammatory lesions . In our study, we chose the emulgel formulation as a topical metformin form to increase the efficacy and absorption in treatment of AV. Emulgel used will be optimized for biocompatibility, consistency and chemical compatibility with metformin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acne Vulgaris

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Single Group Assignment
    Model Description
    Patients will use salicylic acid 30% peeling on the right side of the face and topical metformin emulgel on the left side
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    34 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Topical Metformin Emulgel and salicylic acid
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Topical Metformin Emulgel and salicylic acid
    Intervention Description
    Combination Product: Topical metformin emulgel topical metformin emulgel will be used on the left side of the face twice daily (home use). Procedure/Surgery: Salicylic acid Patients will have salicylic acid 30% peeling on the right side of the face as a peeling session every two weeks. Sessions will be done by well trained physician. Other Names: • 2-hydroxybenzoic acid
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Insulin- Like growth factor (ILGF-1)
    Intervention Description
    3 ml blood for serum sample for estimation of Insulin- Like growth factor (ILGF-1) by ELISA kit will be taken from every patient before and after use of topical metformin.
    Primary Outcome Measure Information:
    Title
    Efficacy of the medications
    Description
    by counting the number of inflammatory, non-inflammatory and total lesions at baseline and every 4 weeks during the treatment.
    Time Frame
    12 weeks
    Title
    Evaluate effect of topical metformin on decreasing serum concentration of insulin-like growth factor 1 (IGF-1)
    Description
    Evaluate effect of topical metformin on decreasing serum concentration of insulin-like growth factor 1 (IGF-1) by serum sample that will be taken from every patient before and after use of topical metformin.
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Assessment of tolerability
    Description
    by interviewing the patients about any sign/symptom of adverse reactions (erythema, peeling, burning sensation, dryness and pruritus).
    Time Frame
    12 weeks
    Title
    Assessment of patient satisfaction
    Description
    by quartile grading system
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Both males and females will be included. Patients older than 18 years of age. Patients with mild and moderate AV. Patients with Fitzpatrick skin type III, IV and V. Exclusion Criteria: Severe acne. Patients under treatment with contraceptive pills or received any kinds of systemic or topical acne medication in the last 2 months (isotretinoin, antibiotics, topical products) or corticosteroid, lithium, growth hormone, systemic metformin, vitamin B12, whey proteins, and estrogenic-progestogens. History of hypertrophic/keloid scar formation. Pregnancy and lactation. Recurrent herpes infection. Subjects with diseases that affect IGF-1 levels such as diabetes, metabolic syndrome, and acromegaly. Conditions that affect liver or thyroid function, celiac disease and inflammatory bowel diseases.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ensaf M Abdel-Maguid, Professor
    Phone
    01005521529
    Email
    ensaf.khalil@med.aun.edu.eg
    First Name & Middle Initial & Last Name or Official Title & Degree
    Heba H Sayed, PHD
    Phone
    01002866919
    Email
    hebahasan16888@yahoo.com

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    Citations:
    PubMed Identifier
    23062156
    Citation
    Titus S, Hodge J. Diagnosis and treatment of acne. Am Fam Physician. 2012 Oct 15;86(8):734-40.
    Results Reference
    background
    PubMed Identifier
    27400809
    Citation
    Han XD, Oon HH, Goh CL. Epidemiology of post-adolescence acne and adolescence acne in Singapore: a 10-year retrospective and comparative study. J Eur Acad Dermatol Venereol. 2016 Oct;30(10):1790-1793. doi: 10.1111/jdv.13743. Epub 2016 Jul 12.
    Results Reference
    background
    PubMed Identifier
    27688440
    Citation
    Hazarika N, Archana M. The Psychosocial Impact of Acne Vulgaris. Indian J Dermatol. 2016 Sep-Oct;61(5):515-20. doi: 10.4103/0019-5154.190102.
    Results Reference
    background
    PubMed Identifier
    21880356
    Citation
    Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29. Erratum In: Lancet. 2012 Jan 28;379(9813):314.
    Results Reference
    background
    PubMed Identifier
    28223742
    Citation
    Kim H, Moon SY, Sohn MY, Lee WJ. Insulin-Like Growth Factor-1 Increases the Expression of Inflammatory Biomarkers and Sebum Production in Cultured Sebocytes. Ann Dermatol. 2017 Feb;29(1):20-25. doi: 10.5021/ad.2017.29.1.20. Epub 2017 Feb 3.
    Results Reference
    background
    PubMed Identifier
    22678562
    Citation
    Kwon HH, Yoon JY, Hong JS, Jung JY, Park MS, Suh DH. Clinical and histological effect of a low glycaemic load diet in treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm Venereol. 2012 May;92(3):241-6. doi: 10.2340/00015555-1346.
    Results Reference
    background
    PubMed Identifier
    27529209
    Citation
    Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules. 2016 Aug 13;21(8):1063. doi: 10.3390/molecules21081063.
    Results Reference
    background
    PubMed Identifier
    20725555
    Citation
    Rendon MI, Berson DS, Cohen JL, Roberts WE, Starker I, Wang B. Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. J Clin Aesthet Dermatol. 2010 Jul;3(7):32-43.
    Results Reference
    background
    PubMed Identifier
    23437788
    Citation
    Badr D, Kurban M, Abbas O. Metformin in dermatology: an overview. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1329-35. doi: 10.1111/jdv.12116. Epub 2013 Feb 26.
    Results Reference
    background
    PubMed Identifier
    26794870
    Citation
    Yuan HX, Guan KL. Structural insights of mTOR complex 1. Cell Res. 2016 Mar;26(3):267-8. doi: 10.1038/cr.2016.10. Epub 2016 Jan 22.
    Results Reference
    background
    PubMed Identifier
    26347269
    Citation
    Arif T. Salicylic acid as a peeling agent: a comprehensive review. Clin Cosmet Investig Dermatol. 2015 Aug 26;8:455-61. doi: 10.2147/CCID.S84765. eCollection 2015.
    Results Reference
    background
    PubMed Identifier
    9620477
    Citation
    Lin AN, Nakatsui T. Salicylic acid revisited. Int J Dermatol. 1998 May;37(5):335-42. doi: 10.1046/j.1365-4362.1998.00452.x. No abstract available.
    Results Reference
    background
    PubMed Identifier
    14725662
    Citation
    Lee HS, Kim IH. Salicylic acid peels for the treatment of acne vulgaris in Asian patients. Dermatol Surg. 2003 Dec;29(12):1196-9; discussion 1199. doi: 10.1111/j.1524-4725.2003.29384.x.
    Results Reference
    background

    Learn more about this trial

    Topical Metformin Emulgel VS Salicylic Acid Peeling in Treatment of Acne Vulgaris

    We'll reach out to this number within 24 hrs